Ketamine Tablets vs IV Infusion

IV infusion and oral tablets represent the two ends of the ketamine delivery spectrum. IV provides maximum drug exposure in a controlled clinical environment. Tablets provide accessible, affordable treatment that patients can manage at home. Understanding the trade-offs between these routes is essential for treatment planning.

Pharmacological Differences

Bioavailability and Metabolism

IV infusion: 100% bioavailability. Every milligram administered reaches the bloodstream as unchanged ketamine. No first-pass metabolism.

Tablets: 10-25% bioavailability. Extensive first-pass hepatic metabolism converts 75-90% to norketamine before reaching systemic circulation. This means a 2.0 mg/kg oral dose delivers roughly the same amount of active ketamine as a 0.2-0.5 mg/kg IV dose.

Onset and Duration

IV: Effects begin within 1-5 minutes. Peak dissociation occurs during the 40-minute infusion. For a detailed comparison of the research evidence, see oral vs. IV comparative research. Effects substantially resolve within 1-2 hours after the infusion ends.

Tablets: Effects begin in 30-60 minutes. Peak effects at 1-2 hours. Total duration of 3-5 hours due to slower absorption and longer norketamine exposure.

Subjective Experience

IV: Intense, immersive dissociation at the standard 0.5 mg/kg dose. Many patients describe profound perceptual changes, emotional experiences, or dream-like states. The experience is powerful and can be either transformative or uncomfortable.

Tablets: Gentler, more gradual effects. Mild to moderate dissociation at typical therapeutic doses. Most patients remain oriented and conversational, though judgment is impaired. Generally described as more manageable.

Clinical Comparison

Efficacy

IV: The evidence base is larger and more robust. Multiple large RCTs demonstrate response rates of 60-70% in TRD within 24 hours of a single infusion. The acute effect is reliable and well-documented.

Tablets: Smaller evidence base but consistently positive results. Response rates of 50-77% in TRD over 1-4 weeks of repeated dosing. Per session, the effect is typically smaller than IV, but cumulative repeated dosing can achieve comparable sustained outcomes.

Setting and Supervision

IV: Requires an infusion clinic with trained nursing staff, cardiac monitoring, IV access, and emergency protocols. The patient must travel to the clinic for every session.

Tablets: Can be taken at home with a treatment monitor present. Requires no clinical infrastructure beyond a prescriber and pharmacy. Blood pressure monitoring at home is recommended but not technically complex.

Cost

IV: $400-$800 per infusion. A standard 6-infusion induction course costs $2,400-$4,800. Maintenance infusions (monthly or bimonthly) add ongoing cost. Rarely covered by insurance for psychiatric indications.

Tablets: $8-$30 per dose from compounding pharmacies. Monthly costs of $200-$600 including clinical oversight. Bundled telehealth services typically $130-$400 per month. Substantially more affordable per month of treatment.

Access

IV: Limited by clinic availability, geography, and scheduling. Patients in rural areas may have no local infusion clinic. Each session requires travel time, clinic time (typically 2-3 hours including monitoring), and a driver home.

Tablets: Available anywhere a prescriber can write a prescription and a compounding pharmacy can ship. Telehealth has made this accessible to nearly any geographic location. Dosing at home eliminates travel burden.

Frequency

IV: Acute induction typically involves 6 infusions over 2-3 weeks. Maintenance is 1 infusion every 2-8 weeks. The frequency is limited by practical and financial constraints.

Tablets: Can be taken 2-3 times weekly during acute treatment, tapering to weekly or biweekly for maintenance. The flexibility to adjust frequency is greater.

When IV Infusion Is the Better Choice

• Acute severe depressive episodes requiring rapid response
• Active suicidal ideation requiring the fastest possible intervention
• Initial treatment induction when a strong first response is the priority
• Patients who have not responded to an adequate trial of oral ketamine
• Clinical situations where supervised administration is essential

When Tablets Are the Better Choice

• Long-term maintenance therapy after initial response
• Geographic or financial barriers to IV clinic access
• Patients who find the IV experience too intense or distressing
• Chronic pain requiring frequent or daily dosing
• Patients with stable conditions appropriate for home-based treatment
• Continuation therapy between IV sessions

The Combined Approach

Many clinicians now use a sequential strategy:

1. Induction (weeks 1-3): IV ketamine infusions (4-6 sessions) to establish acute response
2. Transition (weeks 3-6): Overlapping IV and oral dosing as the patient transitions to tablets
3. Maintenance (months 2+): Ketamine tablets at home, with the IV option available for breakthrough episodes

This approach leverages the strengths of both routes — the reliability and potency of IV for the acute phase, and the practicality and affordability of tablets for the long term.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• Mayo Clinic: Treatment-Resistant Depression — Mayo Clinic resource on treatment-resistant depression diagnosis, management, and emerging therapies